Burns are injuries primarily to the skin and the underlying tissue. The skin is the largest organ in the body and it regulates the body’s temperature. It also prevents the evaporation of body fluids and acts as a barrier against infection.
Skin Burns Market Key Facts
-The total incident population of Skin Burns in the 7 MM was estimated to be approximately 2,881,995 cases out of which 15,49,983 were hospital visit cases in 2017.
-Among the European countries, Germany had the maximum incident cases followed by France.
-Spain had the lowest number of incident cases in 2017 among seven major markets.
-Thermal burns from dry sources (fire or flame) and wet sources (scalds) account for approximately 80 % of all reported burns [ Matthew P. Rowan et. al. 2015].
-Total Severity Specific incident cases in the United States were found to be 602,957 in 2017.
For more details visit: https://www.delveinsight.com/report-store/skin-burns-market
The Herpes Simplex Virus, also known as HSV, is an infection which leads to small, painful, fluid-filled blisters on the skin, mouth, lips, eyes or genitals. This infection is categorized into two types:
Herpes Simplex Virus Type-1 (HSV-1) & Herpes Simplex Virus Type-2 (HSV-2)
-As per WHO’s estimate in 2017, there were about 3.7 billion people under the age 50 (67%) with HSV-1 infection globally and an estimated 417 million people aged 15-49 (11%) worldwide were affected with HSV-2 infection.
-As per the Centers for Disease Control and Prevention, approximately, 776,000 people in the United States develop new Herpes Infections, while one out of every six people aged 14 to 49 years have Genital.
-As per American Academy of Pediatrics, Most people are first exposed to HSV between 1 and 5 years of age.
For more details visit: https://www.delveinsight.com/report-store/herpes-simplex-market
Hepatitis B Virus Infection Market
Hepatitis B is potentially a life-threatening liver infection caused by the Hepatitis B Virus (HBV). It is a major global health problem and it can be an acute infection or a chronic infection. Chronic HBV infection is a leading cause of chronic hepatitis and advanced-stage liver diseases, including cirrhosis and hepatocellular carcinoma (HCC).
-HBV Infection is estimated to have 786,000 deaths and the vast majority being attributable to liver cancer (341,000 deaths) and cirrhosis (312,000 deaths), as per [Lozano et al., 2012].
-According to the WHO, about 2 billion people worldwide have been infected with the Hepatitis B Virus and about 360 million live with chronic Hepatitis B infection.
-The global prevalence of HBV infection varies widely.
-HBV infection ranks 15th among all causes of human mortality [Lozano et al., 2012]
-The global prevalence of HBV infection varies widely. It ranges from <0.5 % in areas of low endemicity (e.g., North America and some Western European countries) to rates above 8% in the highly endemic countries of Sub-Saharan Africa and East Asia.
For more details, visit:
https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-market
Fibrodysplasia Ossificans Progressiva Market
The total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva in the 7MM was 567 in 2017. Females were found to be more affected by Fibrodysplasia Ossificans Progressiva as compared to males. Similarly, a higher prevalence is diagnosed for the age group 20-29.
Increase in research and development, upcoming launch and approval of therapies, awareness of disease are some of the key factors expected to drive the Fibrodysplasia Ossificans Progressiva market in the upcoming years.
The key players in Fibrodysplasia Ossificans Progressiva Market includes Ipsen, Regeneron Pharmaceuticals, AstraZeneca/Amsterdam UMC, Incyte Corporation, Kyoto University/ Takeda and many others.
For more detailed information on Fibrodysplasia Ossificans Progressiva Market, visit: https://www.delveinsight.com/report-store/fibrodysplasia-ossificans-progressiva-fop-market
Hairy Cell Leukemia Market
Hairy Cell Leukemia (HCL) is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. The condition is named after the excess B cells which look ‘hairy’ under a microscope.
Hairy Cell Leukemia Market Key Facts
The total incident population of Hairy Cell Leukemia in the 7 major markets was found to be 2,364 in 2017.
According to the Hairy Cell Leukemia Foundation, the median age at diagnosis of Hairy Cell Leukemia is 58 years and the disease is four-times more common in men than in women.
Around 90 out of every 100 (90%) will survive their leukaemia for 5 years or more after they are diagnosed [Cancer Research UK].
HCL affects about 6,000 persons in the United States. Approximately, 600-800 new cases are diagnosed each year. Most of the affected individuals are males of 50 years of age or older [National Organization for Rare Disorders].
For more details visit:
https://www.delveinsight.com/report-store/hairy-cell-leukemia-hcl-market
Ankylosing spondylitis Market Analysis
Ankylosing spondylitis (AS), also called Bechterew's disease is a form of arthritis that primarily affects the spine, although other joints may also be involved. It causes inflammation of the spinal joints (vertebrae) that can lead to severe, chronic pain and discomfort. It is a type of axial spondyloarthritis (axSpA) that refers to a particular form of spondyloarthritis in which the predominant symptom is inflammatory back pain.
Ankylosing spondylitis Market Key Facts
Ankylosing spondylitis is considered to be more prevalent in men as compared to women.
There were 1,389,116 prevalent cases of Ankylosing Spondylitis in 2017 in 7MM. These prevalent cases are further expected to increase for the study period 2017–2030.
Among the European countries, Germany had the highest prevalent population of Ankylosing Spondylitis with ~374,705 cases, followed by Italy with around 192,013 cases in 2017. Spain had the lowest prevalent pool of Ankylosing Spondylitis in 2017.
Japan had the lowest prevalent population of Ankylosing Spondylitis in 2017 with 7,540 cases in 2017.
AS is found to be more prevalent in men as compared to women, with around 358,880 male and 146,585 female cases in 2017 in the United States. Further in case of severity, majority of cases belong to stable AS (mild), as compared to active AS (moderate to severe)
For more details visit:
https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-market
Alzheimer’s Disease Market Analysis
As per the Alzheimer’s Association, more than 5 million people in the United states are living with Alzheimer’s Disease, and by 2050, the prevalence is projected to propel to nearly 14 million people. Alzheimer’s is the 6th leading cause of death in the USA, it causes more deaths than Prostate and Breast cancer combined.
Women are at a higher risk of developing Alzheimer’s Disease. About two-thirds of the diagnosed AD patients are women.
Some of the key companies are working in the development of new therapeutic options that target specific genetic, molecular, and cellular mechanisms behind the disease in the Alzheimer’s Disease Market. The key players in AD market includes Neurotrope bioscience, Amarantus Bioscience Holdings, AgeneBio, Novartis, Cortexyme, TauRx Therapeutics, Otsuka Pharmaceutical, AC Immune, Genentech, Alkahest, AZ Therapies, Cerecin, vTv Therapeutics, and many others.
The Alzheimer’s Disease market size is anticipated to grow during the forecast period. Some of the key factors expected to drive the Alzheimer’s Disease market includes launch of upcoming therapies, better understanding and better awareness of diseases, increasing morbidity rate due to Alzheimer’s disease and increasing Research and Development in the domain that shall contribute to the development of novel therapeutics and many others.
For more detailed information visit: https://www.delveinsight.com/blog/alzheimers-disease-market/
Technological Devices and Aids to Assist Alzheimer's Patients
Alzheimer’s is a progressive neurological disorder associated with the degeneration of brain cells with time. The progression of disease causes severe impact on the memory, thinking, and overall behavior of the individual, in fact at the later phases it becomes even challenging to perform simple day to day tasks for the affected person.
As per World Health Organization, “nearly 50 million people worldwide are affected with dementia, and there are nearly 10 million new cases every year. Alzheimer disease is the most common form of dementia and contributes around 60–70% of dementia cases”.
The advancement in information and communication technology has brought many revolutionary devices and aids that have significantly improved the life of both Alzheimer’s patients and their caregivers.
Medication Aids, Smart Devices, Hearing Aids, Communication Devices, Virtual Assistants, GPSLocator (Tracking Devices) and few other tech devices has significantly minimized the dependence of Alzheimer’s patients over their caregivers.
For more details visit: https://www.delveinsight.com/blog/technology-and-alzheimers/
Dilated Cardiomyopathy Market Analysis
The total prevalent cases of Dilated Cardiomyopathy in the 7MM are expected to be 2,523,808 in 2020.
The Dilated Cardiomyopathy market is expected to grow with a CAGR of 13.1% in the 7MM during the study period (2017–2030).
Increasing prevalence rate, increased healthcare spending, and emerging treatment options are some of the key factors expected to drive the Dilated Cardiomyopathy market in the upcoming years.
The key players in the Dilated Cardiomyopathy market include Pfizer, MyoKardia, Capricor Therapeutics, Vericel Corporation, Berlin Cures, Cumberland Pharmaceuticals and many others.
For more details visit: https://www.delveinsight.com/report-store/dilated-cardiomyopathy-dcm-market-insights
Prostate Cancer Market Analysis
The total prevalent cases of Prostate Cancer in the 7MM is expected to be 7,494,882 in 2020.
The market size of Prostate Cancer is expected to grow at a CAGR of 8.1% during the study period 2017-2030.
AstraZeneca, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hinova Pharmaceuticals USA, Hoffmann-La Roche, Pfizer/Astellas Pharma, Clovis Oncology, Advantagene, and Merck Sharp & Dohme along with others are the major pharma companies working to fuel the Prostate Cancer market.
For more detailed information on Prostate Cancer Market, visit: https://www.delveinsight.com/report-store/prostate-cancer-market
Dilated Cardiomyopathy Market
According to DelveInsight’s analysis, Dilated Cardiomyopathy prevalence was recorded to be 2,486,633 in 2017, which is expected to be 2,523,808 by 2020 and grow by 2030. The United States accounted for the highest Dilated Cardiomyopathy prevalence in the seven major markets.
The Dilated Cardiomyopathy Market Size in the 7MM is expected to increase from USD 244 Million in 2017 by 2030.
The key companies in the Dilated Cardiomyopathy Market include Pfizer, MyoKardia, Vericel, Capricor Therapeutics, Cumberland Pharmaceuticals, Berlin Cures and others.
For more details visit: https://www.delveinsight.com/blog/dilated-cardiomyopathy-market-dcm-market/
Prostate Cancer Market
As per American Cancer Society (2019), “One in Nine men in the United States is diagnosed with prostate cancer at some point in their lives”.
According to DelveInsight’s Prostate Cancer Epidemiological analysis, by 2020, a total of 7,494,882 males will be diagnosed with prostate cancer in the Seven Major Markets, and the United States alone will account for 3,478,728 Prostate Cancer prevalent cases.
At present, several companies have indulged themselves, their time and money in initiating clinical trials investigating the novel treatments options for Prostate Cancer.
Some of the key Companies in Prostate Cancer Market include AstraZeneca/Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hinova Pharma, Hoffmann-La Roche, Clovis Oncology, Advantagene or Candel Therapeutics, and several others.
For more detailed information visit:
https://www.delveinsight.com/blog/prostate-cancer-market/
HR Positive/ HER2 Negative Breast Cancer Market
HR-positive/HER2-negative breast cancer is the most common form of breast cancer and also accounts for a higher percentage of all breast cancers. HR-positive cancer is usually treated with hormone therapies or a combination of hormone therapies with targeted therapy to help stop tumor growth. A number of classes of anti estrogenic agents available for patients with early, advanced, or metastatic breast cancer includes selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and a selective estrogen receptor degrader.
HR Positive/ HER2 Negative Breast Cancer Market Key Facts
Among the 7MM, the US accounts for the 80.51% USD of the overall market size of ER-positive/HER2-negative Breast Cancer in 2017.
The most incident cases of ER+/HER– breast cancer were recorded in the United States.
The lowest incident population of ER+/HER– breast cancer was recorded in Japan.
Among the EU5 countries, Germany accounts for the highest market size for ER-positive/HER2-negative Breast Cancer followed by France, Italy, the UK, and Spain.
For more details visit:
https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-market-insights
Hemophilia A Market
Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donated whole blood, subsequently by plasma and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A.
Hemophilia A Market Key Facts
Total diagnosed and treated prevalent population of Hemophilia A in the 7MM was assessed to be 38,212 in 2017.
According to DelveInsight’s analysis, the highest prevalent population of Hemophilia A is in the United States with 14,200 cases in 2017.
In the 7MM, approximately 30% of severe hemophilia A cases, i.e., 6,305 patients affected by inhibitors. In addition to this, 70% of the Hemophilia A cases were observed without inhibitors in 2017.
Among the 7MM, the US accounts for 51% USD of the overall market size of hemophilia A in 2017.
Among the European 5 countries, the United Kingdom had the highest prevalent population of Hemophilia A, followed by France and Italy.
For more details visit:
https://www.delveinsight.com/report-store/hemophilia-a2030-market
Diabetic Gastroparesis Market
The term diabetic gastroparesis (DGp) has been used to describe a serious complication of diabetes resulting in delayed gastric emptying with associated upper gastrointestinal (GI) symptoms in the absence of any mechanical obstruction. The usual treatments for DGp include nutritional assessment and dietary modifications, glycemic control, prokinetic agents, and antiemetic agents.
Diabetic Gastroparesis Market Key Facts
Among the 7MM, the US is expected to account for the 62% USD of the overall market size of Diabetic Gastroparesis in 2030.
Among the EU-5 countries, Germany accounts for the highest market size for Diabetic Gastroparesis followed by the United Kingdom, Spain, Italy.
Among the Diabetic Gastroparesis patients, females account for a higher number of Diabetic Gastroparesis cases in comparison to males.
The highest prevalent population of Diabetic Gastroparesis among 7MM is in the United States.
For more details visit:
https://www.delveinsight.com/report-store/diabetic-gastroparesis-market-size
Chronic Hand Eczema Market
Hand eczema (HE) are non-infectious, inflammatory cutaneous lesions and belong to the most common skin disorder affecting the hands. In a substantial number of patients, HE can develop into a chronic condition that remains active even after avoidance of contact with potentially damaging allergens and/or irritants.
Chronic Hand Eczema Market Key Facts
As per DelveInsight estimates, the total prevalent population of Chronic Hand Eczema in 7MM is 4,229,215 cases in 2017. The estimates showed a higher number of cases in females as compared to males
Among the 7MM, the United States accounts for the maximum number of CHE cases with 1,994,070 cases in 2017
The United States accounts for the largest CHE market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan
For more details visit:
https://www.delveinsight.com/report-store/chronic-hand-eczema-market
Early Signs and Symptoms of Alzheimer's
Alzheimer’s is a brain disease. It is an irreversible and progressive disease that generally affects people aged above 65 years but in very rare cases, early-onset has also been noticed in the late ’40s
The onset of Alzheimer’s in the individual can be perceived through early sign and symptoms such as memory loss, Difficulties in operating familiar task, Disassociation from work and social activities, Vision Problem and many others.
As of now, there is no cure for AD, but the medications are available in the market that can temporarily reduce the rate of disease progression. The recognition of early signs and symptoms in the affected individual can help in timely diagnosis and treatment of AD.
For more details visit:
https://www.delveinsight.com/blog/early-signs-of-alzheimers/
Alzheimer’s Disease Market
Alzheimer’s is a progressive disorder which leads to wasting off the brain cells and is one of the most common causes of dementia. The first set of symptoms includes a decline in thinking, behavioural and social skills and disruption in the body’s ability to function start to appear between 40 and 65 years of age.
As per the National Center for Chronic Disease Prevention and Health Promotion, “In 2014, an estimated 5 million Americans aged 65 years or older had Alzheimer’s disease. This number is projected to nearly triple to 14 million people by 2060”.
The key players in the Alzheimer’s disease market at a global level include Neurotrope bioscience, Amarantus Bioscience Holdings, AgeneBio, Novartis, Cortexyme, TauRx Therapeutics, Otsuka Pharmaceutical, AC Immune, Genentech, Alkahest, AZ Therapies, Cerecin, vTv Therapeutics, and others.
For more information visit:
https://www.delveinsight.com/blog/alzheimers-disease-market-trend/
Uveitis Market
Uveitis is the third leading cause of blindness worldwide, and a major one in the United States with a total prevalence of 357,791 in 2017 in the US alone, estimated DelveInsight.
Uveitis or the inflammation in the eye can be due to a pathogen such as bacteria or viruses.
The most Uveitis prevalent cases were observed to be of age-group 18-59 years, whereas, the age group less than 18 years were least affected.
The present Uveitis Market size is expected to grow during the forecast period owing to the launch of upcoming therapies in the 7MM, with the US anticipated to dominate most of the Uveitis Market share.
The key players in the Uveitis market include EyePoint Pharmaceuticals, Alimera Sciences, Clearside Biomedical, Inc., Santen, Oculis S.A., and others.
For more details visit: https://www.delveinsight.com/blog/uveitis-market/
Nontuberculous Mycobacterial Infections Market
The total prevalent population of Nontuberculous Mycobacteria Infection in 7MM is expected to be 3,95,429 by 2030.
The United States accounts for approximately 49% of the total prevalent population in 7MM.
The therapeutic market of Nontuberculous Mycobacteria Infection in 7MM is expected to grow at a CAGR of 6.6% during the study period.
The key players in the Nontuberculous Mycobacteria Infection market include Insmed Inc., RedHill Biopharma, Novoteris, Savara Inc, Beyond Air and others.
For more information visit:
https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market
Joined Feb 2020
